Vascular effects of glycoprotein130 ligands - Part II: Biomarkers and therapeutic targets

Vascular Pharmacology

Volumn 57, Issue 1, 2012, Pages 29-40

  Demyanets, Svitlana ^a   Huber, Kurt ^b   Wojta, Johann ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

^c Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

Author keywords

Biomarkers; Gp130; Gp130 ligands; Therapeutic targets; Vascular disease

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIBODY; ATORVASTATIN; BIOLOGICAL MARKER; CANDESARTAN; CAPTOPRIL; CARDIOTROPHIN 1; CILIARY NEUROTROPHIC FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUINDOSTATIN; FOSINOPRIL; GLYCOPROTEIN GP 130; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 11; INTERLEUKIN 6; IRBESARTAN; LEUKEMIA INHIBITORY FACTOR; LISINOPRIL; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; ONCOSTATIN M; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; QUINAPRIL; RAMIPRIL; RECOMBINANT CYTOKINE; ROSUVASTATIN; SIMVASTATIN; TELMISARTAN; UNINDEXED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COMPARATIVE EFFECTIVENESS; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG INHIBITION; DRUG MEGADOSE; DRUG TARGETING; EXERCISE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; NONHUMAN; NUTRITION; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; STRESS MANAGEMENT; TISSUE LEVEL; VASCULARIZATION; WEIGHT CONTROL;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CYTOKINE RECEPTOR GP130; HUMANS; LIGANDS;

EID: 84862559741     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2011.12.007     Document Type: Review

References (203)

1. Abe Y., Sakaguchi M., Furukado S., Fujinaka T., Sakoda S., Yoshimine T., Kitagawa K. Interleukin-6 release after carotid artery stenting and periprocedural new ischemic lesions. J. Cereb. Blood Flow Metab. 2010, 30:857-863.
2. Abe Y., Sakaguchi M., Furukado S., Okazaki S., Fujinaka T., Sakoda S., Yoshimine T., Kitagawa K. Associations of local release of inflammatory biomarkers during carotid artery stenting with plaque echogenicity and calcification. Cerebrovasc. Dis. 2010, 30:402-409.
3. Aggarwal B.B. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu. Rev. Nutr. 2010, 30:173-199.
4. Aitsebaomo J., Srivastava S., Zhang H., Jha S., Wang Z., Winnik S., Veleva A.N., Pi X., Lockyer P., Faber J.E., Patterson C. Recombinant human interleukin-11 treatment enhances collateral vessel growth after femoral artery ligation. Arterioscler. Thromb. Vasc. Biol. 2011, 31:306-312.
5. Allen T.L., Matthews V.B., Febbraio M.A. Overcoming insulin resistance with ciliary neurotrophic factor. Handb. Exp. Pharmacol. 2011, 179-199.
6. Amer M., Bead V.R., Bathon J., Blumenthal R.S., Edwards D.N. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiol. Rev. 2010, 18:204-212.
7. Andrzejczak D., Gorska D., Czarnecka E. Influence of enalapril, quinapril and losartan on lipopolysaccharide (LPS)-induced serum concentrations of TNF-alpha, IL-1 beta, IL-6 in spontaneously hypertensive rats (SHR). Pharmacol. Rep. 2007, 59:437-446.
8. Anguera I., Miranda-Guardiola F., Bosch X., Filella X., Sitges M., Marin J.L., Betriu A., Sanz G. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am. Heart J. 2002, 144:811-817.
9. Atzeni F., Turiel M., Caporali R., Cavagna L., Tomasoni L., Sitia S., Sarzi-Puttini P. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun. Rev. 2010, 9:835-839.
10. Barderas M.G., Laborde C.M., Posada M., de la Cuesta F., Zubiri I., Vivanco F., Alvarez-Llamas G. Metabolomic profiling for identification of novel potential biomarkers in cardiovascular diseases. J. Biomed. Biotechnol. 2011, 2011:790132.
11. Blake G.J., Ridker P.M. Novel clinical markers of vascular wall inflammation. Circ. Res. 2001, 89:763-771.
12. Brasier A.R. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc. Res. 2010, 86:211-218.
13. Brili S., Tousoulis D., Antoniades C., Vasiliadou C., Karali M., Papageorgiou N., Ioakeimidis N., Marinou K., Stefanadi E., Stefanadis C. Effects of ramipril on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young normotensive subjects with successfully repaired coarctation of aorta: a randomized cross-over study. J. Am. Coll. Cardiol. 2008, 51:742-749.
14. Calabro P., Limongelli G., Riegler L., Maddaloni V., Palmieri R., Golia E., Roselli T., Masarone D., Pacileo G., Golino P., Calabro R. Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. J. Mol. Cell. Cardiol. 2009, 46:142-148.
15. Cesari M., Kritchevsky S.B., Atkinson H.H., Penninx B.W., Di Bari M., Tracy R.P., Pahor M. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am. Heart J. 2009, 157(334):e331-e338.
16. Chujo D., Yagi K., Asano A., Muramoto H., Sakai S., Ohnishi A., Shintaku-Kubota M., Mabuchi H., Yamagishi M., Kobayashi J. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens. Res. 2007, 30:1205-1210.
17. Cola C., Clementi E., Biondi-Zoccai G., Sangiorgi G. From carotid plaque biology to serologic markers of vulnerability to predict the risk of cerebrovascular events. Acta Chir. Belg. 2007, 107:129-142.
18. Coles B., Fielding C.A., Rose-John S., Scheller J., Jones S.A., O'Donnell V.B. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am. J. Pathol. 2007, 171:315-325.
19. Crowe S., Turpin S.M., Ke F., Kemp B.E., Watt M.J. Metabolic remodeling in adipocytes promotes ciliary neurotrophic factor-mediated fat loss in obesity. Endocrinology 2008, 149:2546-2556.
20. Cushman M., Legault C., Barrett-Connor E., Stefanick M.L., Kessler C., Judd H.L., Sakkinen P.A., Tracy R.P. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999, 100:717-722.
21. Cyrus T., Sung S., Zhao L., Funk C.D., Tang S., Pratico D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2002, 106:1282-1287.
22. Dandona P., Dhindsa S., Ghanim H., Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J. Hum. Hypertens. 2007, 21:20-27.
23. Dasu M.R., Park S., Devaraj S., Jialal I. Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 2009, 150:3457-3464.
24. Dawson J., Cockerill G.W., Choke E., Belli A.M., Loftus I., Thompson M.M. Aortic aneurysms secrete interleukin-6 into the circulation. J. Vasc. Surg. 2007, 45:350-356.
25. de Bont N., Netea M.G., Rovers C., Smilde T., Demacker P.N., van der Meer J.W., Stalenhoef A.F. LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors. Atherosclerosis 1998, 139:147-152.
26. del Porto F., Proietta M., Tritapepe L., Miraldi F., Koverech A., Cardelli P., Tabacco F., de Santis V., Vecchione A., Mitterhofer A.P., Nofroni I., Amodeo R., Trappolini M., Aliberti G. Inflammation and immune response in acute aortic dissection. Ann. Med. 2010, 42:622-629.
27. Demyanets S., Kaun C., Maurer G., Huber K., Wojta J. Statins modulate expression of components of the plasminogen activator/plasmin system in human cardiac myocytes in vitro. J. Thromb. Haemost. 2006, 4:476-479.
28. Demyanets S., Kaun C., Pfaffenberger S., Hohensinner P.J., Rega G., Pammer J., Maurer G., Huber K., Wojta J. Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro. Biochem. Pharmacol. 2006, 71:1324-1330.
29. Demyanets S., Pfaffenberger S., Kaun C., Rega G., Speidl W.S., Kastl S.P., Weiss T.W., Hohensinner P.J., Dietrich W., Tschugguel W., Bochkov V.N., Awad E.M., Maurer G., Huber K., Wojta J. The estrogen metabolite 17beta-dihydroequilenin counteracts interleukin-1alpha induced expression of inflammatory mediators in human endothelial cells in vitro via NF-kappaB pathway. Thromb. Haemost. 2006, 95:107-116.
30. Derouet D., Rousseau F., Alfonsi F., Froger J., Hermann J., Barbier F., Perret D., Diveu C., Guillet C., Preisser L., Dumont A., Barbado M., Morel A., deLapeyriere O., Gascan H., Chevalier S. Neuropoietin, a new IL-6-related cytokine signaling through the ciliary neurotrophic factor receptor. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:4827-4832.
31. Detmer K., Wang Z., Warejcka D., Leeper-Woodford S.K., Newman W.H. Endotoxin stimulated cytokine production in rat vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 2001, 281:H661-H668.
32. Dimitrow P.P., Jawien M. Pleiotropic, cardioprotective effects of omega-3 polyunsaturated fatty acids. Mini Rev. Med. Chem. 2009, 9:1030-1039.
33. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998, 279:1615-1622.
34. Du X., Liu Q., Yang Z., Orazi A., Rescorla F.J., Grosfeld J.L., Williams D.A. Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis. Am. J. Physiol. 1997, 272:G545-G552.
35. Eder K., Baffy N., Falus A., Fulop A.K. The major inflammatory mediator interleukin-6 and obesity. Inflamm. Res. 2009, 58:727-736.
36. Elhage R., Clamens S., Besnard S., Mallat Z., Tedgui A., Arnal J., Maret A., Bayard F. Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis 2001, 156:315-320.
37. Erbel C., Dengler T.J., Wangler S., Lasitschka F., Bea F., Wambsganss N., Hakimi M., Bockler D., Katus H.A., Gleissner C.A. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res. Cardiol. 2011, 106:125-134.
38. Ettinger M.P., Littlejohn T.W., Schwartz S.L., Weiss S.R., McIlwain H.H., Heymsfield S.B., Bray G.A., Roberts W.G., Heyman E.R., Stambler N., Heshka S., Vicary C., Guler H.P. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 2003, 289:1826-1832.
39. Febbraio M.A. gp130 receptor ligands as potential therapeutic targets for obesity. J. Clin. Invest. 2007, 117:841-849.
40. Ferguson C.D., Clancy P., Bourke B., Walker P.J., Dear A., Buckenham T., Norman P., Golledge J. Association of statin prescription with small abdominal aortic aneurysm progression. Am. Heart J. 2010, 159:307-313.
41. Fischer P., Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. Basic Res. Cardiol. 2007, 102:393-411.
42. Fisman E.Z., Tenenbaum A. The ubiquitous interleukin-6: a time for reappraisal. Cardiovasc. Diabetol. 2010, 9:62.
43. Flondell-Site D., Lindblad B., Kolbel T., Gottsater A. Cytokines and systemic biomarkers are related to the size of abdominal aortic aneurysms. Cytokine 2009, 46:211-215.
44. Fragoso J.M., Delgadillo H., Juarez-Cedillo T., Rodriguez-Perez J.M., Vallejo M., Perez-Mendez O., Alvarez-Leon E., Pena-Duque M.A., Martinez-Rios M.A., Vargas-Alarcon G. The interleukin 6-572 G>C (rs1800796) polymorphism is associated with the risk of developing acute coronary syndrome. Genet. Test. Mol. Biomarkers 2010, 14:759-763.
45. Franklin I.J., Walton L.J., Brown L., Greenhalgh R.N., Powell J.T. Vascular surgical society of great britain and ireland: non-steroidal anti-inflammatory drugs to treat abdominal aortic aneurysm. Br. J. Surg. 1999, 86:707.
46. Fujimoto H., Hirase T., Miyazaki Y., Hara H., Ide-Iwata N., Nishimoto-Hazuku A., Saris C.J., Yoshida H., Node K. IL-27 inhibits hyperglycemia and pancreatic islet inflammation induced by streptozotocin in mice. Am. J. Pathol. 2011, 179:2327-2336.
47. Gach O., Biemar C., Nys M., Deby-Dupont G., Chapelle J.P., Deby C., Lamy M., Pierard L.A., Legrand V. Early release of neutrophil markers of activation after direct stenting in patients with unstable angina. Coron. Artery Dis. 2005, 16:59-65.
48. Gadient R.A., Patterson P.H. Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Stem Cells 1999, 17:127-137.
49. Gaesser G.A. Exercise for prevention and treatment of cardiovascular disease, type 2 diabetes, and metabolic syndrome. Curr. Diab. Rep. 2007, 7:14-19.
50. Gibas M., Miszczak-Smialek J., Madry E., Gluszek J., Witmanowski H., Piotrowski J. Influence of preventive therapy with quinapril on IL-6 level in patients with chronic stable angina. Pharmacol. Rep. 2007, 59:330-338.
51. Gonzalez A., Lopez B., Ravassa S., Beaumont J., Arias T., Hermida N., Zudaire A., Diez J. Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovasc. Res. 2009, 81:509-518.
52. Gordon M.S., McCaskill-Stevens W.J., Battiato L.A., Loewy J., Loesch D., Breeden E., Hoffman R., Beach K.J., Kuca B., Kaye J., Sledge G.W. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996, 87:3615-3624.
53. Grothusen C., Bley S., Selle T., Luchtefeld M., Grote K., Tietge U.J., Drexler H., Schieffer B. Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis. Atherosclerosis 2005, 182:57-69.
54. Gwechenberger M., Pacher R., Berger R., Zorn G., Moser P., Stanek B., Huelsmann M. Comparison of soluble glycoprotein 130 and cardiac natriuretic peptides as long-term predictors of heart failure progression. J. Heart Lung Transplant. 2005, 24:2190-2195.
55. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002, 106:679-684.
56. Heald M., Cawthorne M.A. Dual acting and pan-PPAR activators as potential anti-diabetic therapies. Handb. Exp. Pharmacol. 2011, 35-51.
57. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
58. Heinrich P.C., Castell J.V., Andus T. Interleukin-6 and the acute phase response. Biochem. J. 1990, 265:621-636.
59. Herder C., Karakas M., Koenig W. Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin. Pharmacol. Ther. 2011, 90:52-66.
60. Hochholzer W., Morrow D.A., Giugliano R.P. Novel biomarkers in cardiovascular disease: update 2010. Am. Heart J. 2010, 160:583-594.
61. Hodgson J.M., Croft K.D. Tea flavonoids and cardiovascular health. Mol. Aspects Med. 2010, 31:495-502.
62. Hong S.J., Shim W.J., Choi J.I., Joo H.J., Shin S.Y., Park S.M., Lim S.Y., Lim D.S. Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. Am. J. Cardiol. 2007, 100:1625-1629.
63. Hovens M.M., Snoep J.D., Groeneveld Y., Frolich M., Tamsma J.T., Huisman M.V. Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial. Diabetes Obes. Metab. 2008, 10:668-674.
64. Hwang J., Lee K.E., Lim J.Y., Park S.I. Nitrated fatty acids prevent TNFalpha-stimulated inflammatory and atherogenic responses in endothelial cells. Biochem. Biophys. Res. Commun. 2009, 387:633-640.
65. Ikonomidis I., Andreotti F., Economou E., Stefanadis C., Toutouzas P., Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999, 100:793-798.
66. Inta I., Weber D., Grundt C., Veltkamp R., Winteroll S., Auffarth G.U., Bettendorf M., Lemmer B., Schwaninger M. Correlation of soluble gp130 serum concentrations with arterial blood pressure. J. Hypertens. 2009, 27:527-534.
67. Ishikawa M., Saito Y., Miyamoto Y., Harada M., Kuwahara K., Ogawa E., Nakagawa O., Hamanaka I., Kajiyama N., Takahashi N., Masuda I., Hashimoto T., Sakai O., Hosoya T., Nakao K. A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats. J. Hypertens. 1999, 17:807-816.
68. Ito T., Ikeda U., Shimpo M., Ohki R., Takahashi M., Yamamoto K., Shimada K. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc. Drugs Ther. 2002, 16:121-126.
69. Jarai R., Kaun C., Weiss T.W., Speidl W.S., Rychli K., Maurer G., Huber K., Wojta J. Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1alpha, tumour necrosis factor-alpha and transforming growth factor-beta. J. Cell. Mol. Med. 2009, 13:4415-4421.
70. Jazayeri J.A., Upadhyay A., Vernallis A.B., Carroll G.J. Targeting the glycoprotein 130 receptor subunit to control pain and inflammation. J. Interferon Cytokine Res. 2010, 30:865-873.
71. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
72. Jones A., Deb R., Torsney E., Howe F., Dunkley M., Gnaneswaran Y., Gaze D., Nasr H., Loftus I.M., Thompson M.M., Cockerill G.W. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation 2009, 119:3125-3132.
73. Jones K.G., Brull D.J., Brown L.C., Sian M., Greenhalgh R.M., Humphries S.E., Powell J.T. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001, 103:2260-2265.
74. Jones S.A., Scheller J., Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 2011, 121:3375-3383.
75. Jostock T., Mullberg J., Ozbek S., Atreya R., Blinn G., Voltz N., Fischer M., Neurath M.F., Rose-John S. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 2001, 268:160-167.
76. Khan S.Q., Kelly D., Quinn P., Davies J.E., Ng L.L. Cardiotrophin-1 predicts death or heart failure following acute myocardial infarction. J. Card. Fail. 2006, 12:635-640.
77. Kim Y.S., Ahn Y., Hong M.H., Kim K.H., Park H.W., Hong Y.J., Kim J.H., Kim W., Jeong M.H., Cho J.G., Park J.C., Kang J.C. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells. J. Cardiovasc. Pharmacol. 2007, 49:376-383.
78. Kishimoto T. IL-6: from its discovery to clinical applications. Int. Immunol. 2010, 22:347-352.
79. Kizu A., Shioi A., Jono S., Koyama H., Okuno Y., Nishizawa Y. Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators. J. Cell. Biochem. 2004, 93:1011-1019.
80. Klitkou J., Jensen L.O., Hansen H.S., Thayssen P. High sensitive C-reactive protein and interleukin 6 are not related to neointimal hyperplasia in paclitaxel eluting stents or bare metal stents. An intravascular ultrasound study. Int. J. Cardiol. 2007, 119:114-116.
81. Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease - a perspective. Drug Des. Devel. Ther. 2010, 4:383-413.
82. Kyurkchiev D., Ivanova-Todorova E., Hayrabedyan S., Altankova I., Kyurkchiev S. Female sex steroid hormones modify some regulatory properties of monocyte-derived dendritic cells. Am. J. Reprod. Immunol. 2007, 58:425-433.
83. Lai P.C., Cook H.T., Smith J., Keith J.C., Pusey C.D., Tam F.W. Interleukin-11 attenuates nephrotoxic nephritis in Wistar Kyoto rats. J. Am. Soc. Nephrol. 2001, 12:2310-2320.
84. Laimer M., Ebenbichler C.F., Kaser S., Sandhofer A., Weiss H., Nehoda H., Aigner F., Patsch J.R. Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. Int. J. Obes. Relat. Metab. Disord. 2002, 26:659-662.
85. Laimer M., Kaser S., Kranebitter M., Sandhofer A., Muhlmann G., Schwelberger H., Weiss H., Patsch J.R., Ebenbichler C.F. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int. J. Obes. (Lond) 2005, 29:498-501.
86. Lambert P.D., Anderson K.D., Sleeman M.W., Wong V., Tan J., Hijarunguru A., Corcoran T.L., Murray J.D., Thabet K.E., Yancopoulos G.D., Wiegand S.J. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:4652-4657.
87. Lee G., Kil G., Kwon J., Kim S., Yoo J., Shin J. Oncostatin M as a target biological molecule of preeclampsia. J. Obstet. Gynaecol. Res. 2009, 35:869-875.
88. Li J.J., Chen X.J. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron. Artery Dis. 2003, 14:329-334.
89. Li S., Li X., Li Y. Regulation of atherosclerotic plaque growth and stability by testosterone and its receptor via influence of inflammatory reaction. Vascul. Pharmacol. 2008, 49:14-18.
90. Liang Y.J., Liu Y.C., Chen C.Y., Lai L.P., Shyu K.G., Juang S.J., Wang B.W., Leu J.G. Comparison of PPARdelta and PPARgamma in inhibiting the pro-inflammatory effects of C-reactive protein in endothelial cells. Int. J. Cardiol. 2010, 143:361-367.
91. Lindmark E., Diderholm E., Wallentin L., Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 2001, 286:2107-2113.
92. Lindmark E., Siegbahn A. Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin. Thromb. Res. 2002, 108:77-84.
93. Link A., Lenz M., Legner D., Bohm M., Nickenig G. Telmisartan inhibits beta2-integrin MAC-1 expression in human T-lymphocytes. J. Hypertens. 2006, 24:1891-1898.
94. Lippert T.H., Mueck A.O., Seeger H. Is the use of conjugated equine oestrogens in hormone replacement therapy still appropriate?. Br. J. Clin. Pharmacol. 2000, 49:489-490.
95. Lloyd P.G., Sheehy A.J., Edwards J.M., Mokelke E.A., Sturek M. Leukemia inhibitory factor is upregulated in coronary arteries of Ossabaw miniature swine after stent placement. Coron. Artery Dis. 2008, 19:217-226.
96. Lopez B., Gonzalez A., Lasarte J.J., Sarobe P., Borras F., Diaz A., Barba J., Tomas L., Lozano E., Serrano M., Varo N., Beloqui O., Fortuno M.A., Diez J. Is plasma cardiotrophin-1 a marker of hypertensive heart disease?. J. Hypertens. 2005, 23:625-632.
97. Loppnow H., Zhang L., Buerke M., Lautenschlager M., Chen L., Frister A., Schlitt A., Luther T., Song N., Hofmann B., Rose-John S., Silber R.E., Muller-Werdan U., Werdan K. Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. J. Cell. Mol. Med. 2011, 15:994-1004.
98. Luc G., Bard J.M., Juhan-Vague I., Ferrieres J., Evans A., Amouyel P., Arveiler D., Fruchart J.C., Ducimetiere P. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1255-1261.
99. Luchtefeld M., Schunkert H., Stoll M., Selle T., Lorier R., Grote K., Sagebiel C., Jagavelu K., Tietge U.J., Assmus U., Streetz K., Hengstenberg C., Fischer M., Mayer B., Maresso K., El Mokhtari N.E., Schreiber S., Muller W., Bavendiek U., Grothusen C., Drexler H., Trautwein C., Broeckel U., Schieffer B. Signal transducer of inflammation gp130 modulates atherosclerosis in mice and man. J. Exp. Med. 2007, 204:1935-1944.
100. Madej A., Buldak L., Basiak M., Szkrobka W., Dulawa A., Okopien B. The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines. Int. J. Clin. Pharmacol. Ther. 2009, 47:686-694.
101. Matthews V.B., Febbraio M.A. CNTF: a target therapeutic for obesity-related metabolic disease?. J. Mol. Med. Berl. 2008, 86:353-361.
102. 14+ monocytes. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1439-1445.
103. Millar J.S., Ky B., Wolfe M.L., Pruscino L., Baer A., Rader D.J. Short-term treatment with high-dose atorvastatin reduces LDL cholesterol but shows no anti-inflammatory effects in normolipidemic subjects with normal CRP levels. Clin. Transl. Sci. 2010, 3:140-146.
104. Miller A.P., Chen Y.F., Xing D., Feng W., Oparil S. Hormone replacement therapy and inflammation: interactions in cardiovascular disease. Hypertension 2003, 42:657-663.
105. Miller A.P., Feng W., Xing D., Weathington N.M., Blalock J.E., Chen Y.F., Oparil S. Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries. Circulation 2004, 110:1664-1669.
106. Monakier D., Mates M., Klutstein M.W., Balkin J.A., Rudensky B., Meerkin D., Tzivoni D. Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. Chest 2004, 125:1610-1615.
107. Montalescot G., Drexler H., Gallo R., Pearson T., Thoenes M., Bhatt D.L. Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study. Eur. Heart J. 2009, 30:2733-2741.
108. Moorehead P., Mandel K.M., Johnston D.L. Suspected interaction of oprelvekin (rhIL-11) with a long-acting opioid. Pediatr. Blood Cancer 2008, 51:837.
109. Moran C.S., Campbell J.H., Campbell G.R. Human leukemia inhibitory factor upregulates LDL receptors on liver cells and decreases serum cholesterol in the cholesterol-fed rabbit. Arterioscler. Thromb. Vasc. Biol. 1997, 17:1267-1273.
110. Moran C.S., Campbell J.H., Campbell G.R. Induction of smooth muscle cell nitric oxide synthase by human leukaemia inhibitory factor: effects in vitro and in vivo. J. Vasc. Res. 1997, 34:378-385.
111. Moran C.S., Campbell J.H., Simmons D.L., Campbell G.R. Human leukemia inhibitory factor inhibits development of experimental atherosclerosis. Arterioscler. Thromb. 1994, 14:1356-1363.
112. Moreno-Aliaga M.J., Perez-Echarri N., Marcos-Gomez B., Larequi E., Gil-Bea F.J., Viollet B., Gimenez I., Martinez J.A., Prieto J., Bustos M. Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab. 2011, 14:242-253.
113. Mulvihill N.T., Foley J.B. Inflammation in acute coronary syndromes. Heart 2002, 87:201-204.
114. Murphy M., Dutton R., Koblar S., Cheema S., Bartlett P. Cytokines which signal through the LIF receptor and their actions in the nervous system. Prog. Neurobiol. 1997, 52:355-378.
115. Naito M., Shenoy A., Aoyama I., Koopmeiners J.S., Komers R., Schnaper H.W., Bomsztyk K. High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin. Am. J. Nephrol. 2009, 30:99-111.
116. Niessner A., Richter B., Penka M., Steiner S., Strasser B., Ziegler S., Heeb-Elze E., Zorn G., Leitner-Heinschink A., Niessner C., Wojta J., Huber K. Endurance training reduces circulating inflammatory markers in persons at risk of coronary events: impact on plaque stabilization?. Atherosclerosis 2006, 186:160-165.
117. Nishimoto N., Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb. Exp. Pharmacol. 2008, 151-160.
118. Pan H.C., Yang D.Y., Ou Y.C., Ho S.P., Cheng F.C., Chen C.J. Neuroprotective effect of atorvastatin in an experimental model of nerve crush injury. Neurosurgery 2010, 67:376-388. discussion 388-379.
119. Paoletti R., Gotto A.M., Hajjar D.P. Inflammation in atherosclerosis and implications for therapy. Circulation 2004, 109:III20-III26.
120. Patel L., Charlton S.J., Marshall I.C., Moore G.B., Coxon P., Moores K., Clapham J.C., Newman S.J., Smith S.A., Macphee C.H. PPARgamma is not a critical mediator of primary monocyte differentiation or foam cell formation. Biochem. Biophys. Res. Commun. 2002, 290:707-712.
121. Paul A., Calleja L., Camps J., Osada J., Vilella E., Ferre N., Mayayo E., Joven J. The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. Life Sci. 2000, 68:457-465.
122. Pedersen B.K., Febbraio M.A. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol. Rev. 2008, 88:1379-1406.
123. Peeters K., Stassen J.M., Collen D., Van Geet C., Freson K. Emerging treatments for thrombocytopenia: increasing platelet production. Drug Discov. Today 2008, 13:798-806.
124. Peeters W., Hellings W.E., de Kleijn D.P., de Vries J.P., Moll F.L., Vink A., Pasterkamp G. Carotid atherosclerotic plaques stabilize after stroke: insights into the natural process of atherosclerotic plaque stabilization. Arterioscler. Thromb. Vasc. Biol. 2009, 29:128-133.
125. Pflanz S., Timans J.C., Cheung J., Rosales R., Kanzler H., Gilbert J., Hibbert L., Churakova T., Travis M., Vaisberg E., Blumenschein W.M., Mattson J.D., Wagner J.L., To W., Zurawski S., McClanahan T.K., Gorman D.M., Bazan J.F., de Waal Malefyt R., Rennick D., Kastelein R.A. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002, 16:779-790.
126. Pierce J.W., Read M.A., Ding H., Luscinskas F.W., Collins T. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J. Immunol. 1996, 156:3961-3969.
127. Pradeep A.R., S TM, Garima G., Raju A. Serum levels of oncostatin M (a gp 130 cytokine): an inflammatory biomarker in periodontal disease. Biomarkers 2010, 15:277-282.
128. Pradhan A.D., Manson J.E., Rossouw J.E., Siscovick D.S., Mouton C.P., Rifai N., Wallace R.B., Jackson R.D., Pettinger M.B., Ridker P.M. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002, 288:980-987.
129. Pratico D., Tillmann C., Zhang Z.B., Li H., FitzGerald G.A. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:3358-3363.
130. Premaratna S.D., Manickam E., Begg D.P., Rayment D.J., Hafandi A., Jois M., Cameron-Smith D., Weisinger R.S. Angiotensin-converting enzyme inhibition reverses diet-induced obesity, insulin resistance and inflammation in C57BL/6J mice. Int. J. Obes. 2011, (Lond).
131. Putoczki T., Ernst M. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J. Leukoc. Biol. 2010, 88:1109-1117.
132. Rabe B., Chalaris A., May U., Waetzig G.H., Seegert D., Williams A.S., Jones S.A., Rose-John S., Scheller J. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008, 111:1021-1028.
133. Ragni M.V., Jankowitz R.C., Chapman H.L., Merricks E.P., Kloos M.T., Dillow A.M., Nichols T.C. A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease. Haemophilia 2008, 14:968-977.
134. Rajasingh J., Bright J.J. 15-Deoxy-delta12,14-prostaglandin J2 regulates leukemia inhibitory factor signaling through JAK-STAT pathway in mouse embryonic stem cells. Exp. Cell Res. 2006, 312:2538-2546.
135. Register T.C., Cann J.A., Kaplan J.R., Williams J.K., Adams M.R., Morgan T.M., Anthony M.S., Blair R.M., Wagner J.D., Clarkson T.B. Effects of soy isoflavones and conjugated equine estrogens on inflammatory markers in atherosclerotic, ovariectomized monkeys. J. Clin. Endocrinol. Metab. 2005, 90:1734-1740.
136. Reis E.D., Roque M., Dansky H., Fallon J.T., Badimon J.J., Cordon-Cardo C., Shiff S.J., Fisher E.A. Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:12764-12769.
137. Reynolds C.H. Clinical efficacy of rhIL-11. Oncology (Williston Park) 2000, 14:32-40.
138. Rezaie-Majd A., Maca T., Bucek R.A., Valent P., Muller M.R., Husslein P., Kashanipour A., Minar E., Baghestanian M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1194-1199.
139. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
140. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 2000, 342:836-843.
141. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
142. Rioja I., Hughes F.J., Sharp C.H., Warnock L.C., Montgomery D.S., Akil M., Wilson A.G., Binks M.H., Dickson M.C. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum. 2008, 58:2257-2267.
143. Robertson L., Grip L., Mattsson Hulten L., Hulthe J., Wiklund O. Release of protein as well as activity of MMP-9 from unstable atherosclerotic plaques during percutaneous coronary intervention. J. Intern. Med. 2007, 262:659-667.
144. Robson-Ansley P., Cockburn E., Walshe I., Stevenson E., Nimmo M. The effect of exercise on plasma soluble IL-6 receptor concentration: a dichotomous response. Exerc. Immunol. Rev. 2010, 16:56-76.
145. Roger V.L., Go A.S., Lloyd-Jones D.M., Adams R.J., Berry J.D., Brown T.M., Carnethon M.R., Dai S., de Simone G., Ford E.S., Fox C.S., Fullerton H.J., Gillespie C., Greenlund K.J., Hailpern S.M., Heit J.A., Ho P.M., Howard V.J., Kissela B.M., Kittner S.J., Lackland D.T., Lichtman J.H., Lisabeth L.D., Makuc D.M., Marcus G.M., Marelli A., Matchar D.B., McDermott M.M., Meigs J.B., Moy C.S., Mozaffarian D., Mussolino M.E., Nichol G., Paynter N.P., Rosamond W.D., Sorlie P.D., Stafford R.S., Turan T.N., Turner M.B., Wong N.D., Wylie-Rosett J. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
146. Rolfe B.E., Stamatiou S., World C.J., Brown L., Thomas A.C., Bingley J.A., Worth N.F., Campbell J.H. Leukaemia inhibitory factor retards the progression of atherosclerosis. Cardiovasc. Res. 2003, 58:222-230.
147. Ryan K.E., McCance D.R., Powell L., McMahon R., Trimble E.R. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 2007, 194:e123-e130.
148. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 1996, 335:1001-1009.
149. Samaha F.F., Szapary P.O., Iqbal N., Williams M.M., Bloedon L.T., Kochar A., Wolfe M.L., Rader D.J. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2006, 26:624-630.
150. Sands B.E., Winston B.D., Salzberg B., Safdi M., Barish C., Wruble L., Wilkins R., Shapiro M., Schwertschlag U.S. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment. Pharmacol. Ther. 2002, 16:399-406.
151. Santini E., Madec S., Corretti V., Ferrannini E., Solini A. Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients. J. Endocrinol. Invest. 2008, 31:660-665.
152. Sanz-Rosa D., Oubina M.P., Cediel E., de Las Heras N., Vegazo O., Jimenez J., Lahera V., Cachofeiro V. Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H111-H115.
153. Schaefer J.R. Lipid management for the prevention of cardiovascular disease. Curr. Pharm. Des. 2011, 17:852-860.
154. Scheller J., Chalaris A., Schmidt-Arras D., Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 2011, 1813:878-888.
155. Scheller J., Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med. Microbiol. Immunol. 2006, 195:173-183.
156. Schieffer B., Bunte C., Witte J., Hoeper K., Boger R.H., Schwedhelm E., Drexler H. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J. Am. Coll. Cardiol. 2004, 44:362-368.
157. Schuett H., Luchtefeld M., Grothusen C., Grote K., Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb. Haemost. 2009, 102:215-222.
158. Semenova A.E., Sergienko I.V., Masenko V.P., Ezhov M.V., Gabrusenko S.A., Kuharchuk V.V., Belenkov Y.N. The influence of rosuvastatin therapy and percutaneous coronary intervention on angiogenic growth factors in coronary artery disease patients. Acta Cardiol. 2009, 64:405-409.
159. Silver J.S., Hunter C.A. gp130 at the nexus of inflammation, autoimmunity, and cancer. J. Leukoc. Biol. 2010, 88:1145-1156.
160. Sims N.A., Walsh N.C. GP130 cytokines and bone remodelling in health and disease. BMB Rep. 2010, 43:513-523.
161. Slevin M., Krupinski J., Kumar P., Gaffney J., Kumar S. Gene activation and protein expression following ischaemic stroke: strategies towards neuroprotection. J. Cell. Mol. Med. 2005, 9:85-102.
162. Slevin M., Krupinski J., Mitsios N., Perikleous C., Cuadrado E., Montaner J., Sanfeliu C., Luque A., Kumar S., Kumar P., Gaffney J. Leukaemia inhibitory factor is over-expressed by ischaemic brain tissue concomitant with reduced plasma expression following acute stroke. Eur. J. Neurol. 2008, 15:29-37.
163. Solheim S., Arnesen H., Eikvar L., Hurlen M., Seljeflot I. Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am. J. Cardiol. 2003, 92:843-845.
164. Sotiriou C., Lacroix M., Lagneaux L., Berchem G., Body J.J. The aspirin metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines interleukins-6 and -11. Anticancer Res. 1999, 19:2997-3006.
165. Speidl W.S., Exner M., Amighi J., Kastl S.P., Zorn G., Maurer G., Wagner O., Huber K., Minar E., Wojta J., Schillinger M. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur. Heart J. 2005, 26:2294-2299.
166. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998, 393:790-793.
167. Steptoe A., Willemsen G., Owen N., Flower L., Mohamed-Ali V. Acute mental stress elicits delayed increases in circulating inflammatory cytokine levels. Clin. Sci. (Lond.) 2001, 101:185-192.
168. Sukovich D.A., Kauser K., Shirley F.D., DelVecchio V., Halks-Miller M., Rubanyi G.M. Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice: inhibition by 17beta-estradiol. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1498-1505.
169. Szkodzinski J., Blazelonis A., Wilczek K., Hudzik B., Romanowski W., Gasior M., Wojnar R., Lekston A., Polonski L., Zubelewicz-Szkodzinska B. The role of interleukin-6 and transforming growth factor-beta1 in predicting restenosis within stented infarct-related artery. Int. J. Immunopathol. Pharmacol. 2009, 22:493-500.
170. Takata Y., Kitami Y., Yang Z.H., Nakamura M., Okura T., Hiwada K. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma. Circ. Res. 2002, 91:427-433.
171. Talwar S., Squire I.B., O'Brien R.J., Downie P.F., Davies J.E., Ng L.L. Plasma cardiotrophin-1 following acute myocardial infarction: relationship with left ventricular systolic dysfunction. Clin. Sci. (Lond.) 2002, 102:9-14.
172. Taylor H.S., Manson J.E. Update in hormone therapy use in menopause. J. Clin. Endocrinol. Metab. 2011, 96:255-264.
173. Tepler I., Elias L., Smith J.W., Hussein M., Rosen G., Chang A.Y., Moore J.O., Gordon M.S., Kuca B., Beach K.J., Loewy J.W., Garnick M.B., Kaye J.A. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996, 87:3607-3614.
174. Tian Q., Miyazaki R., Ichiki T., Imayama I., Inanaga K., Ohtsubo H., Yano K., Takeda K., Sunagawa K. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta. Hypertension 2009, 53:798-804.
175. Tieu B.C., Lee C., Sun H., Lejeune W., Recinos A., Ju X., Spratt H., Guo D.C., Milewicz D., Tilton R.G., Brasier A.R. An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. J. Clin. Invest. 2009, 119:3637-3651.
176. Tiran A., Gruber H.J., Graier W.F., Wagner A.H., Van Leeuwen E.B., Tiran B. Aspirin inhibits Chlamydia pneumoniae-induced nuclear factor-kappa B activation, cytokine expression, and bacterial development in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1075-1080.
177. Title L.M., Giddens K., McInerney M.M., McQueen M.J., Nassar B.A. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J. Am. Coll. Cardiol. 2003, 42:1747-1753.
178. Tsakiris D.A., Tschopl M., Wolf F., Labs K.H., Jager K.A., Marbet G.A. Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease. Blood Coagul. Fibrinolysis 2000, 11:165-173.
179. Valkeinen H., Aaltonen S., Kujala U.M. Effects of exercise training on oxygen uptake in coronary heart disease: a systematic review and meta-analysis. Scand. J. Med. Sci. Sports 2010, 20:545-555.
180. Vanderlocht J., Hendriks J.J., Venken K., Stinissen P., Hellings N. Effects of IFN-beta, leptin and simvastatin on LIF secretion by T lymphocytes of MS patients and healthy controls. J. Neuroimmunol. 2006, 177:189-200.
181. Verhoeven B.A., Moll F.L., Koekkoek J.A., van der Wal A.C., de Kleijn D.P., de Vries J.P., Verheijen J.H., Velema E., Busser E., Schoneveld A., Virmani R., Pasterkamp G. Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy. Stroke 2006, 37:2054-2060.
182. Vincent L., Chen W., Hong L., Mirshahi F., Mishal Z., Mirshahi-Khorassani T., Vannier J.P., Soria J., Soria C. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett. 2001, 495:159-166.
183. Wadhwa M., Thorpe R. Haematopoietic growth factors and their therapeutic use. Thromb. Haemost. 2008, 99:863-873.
184. Wakatsuki A., Okatani Y., Ikenoue N., Fukaya T. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 2002, 105:1436-1439.
185. Wallinder J., Bergqvist D., Henriksson A.E. Proinflammatory and anti-inflammatory cytokine balance in patients with abdominal aortic aneurysm and the impact of aneurysm size. Vasc. Endovascular Surg. 2009, 43:258-261.
186. Wallinder J., Skagius E., Bergqvist D., Henriksson A.E. Early inflammatory response in patients with ruptured abdominal aortic aneurysm. Vasc. Endovascular Surg. 2010, 44:32-35.
187. Wang D., Liu Z., Li Q., Karpurapu M., Kundumani-Sridharan V., Cao H., Dronadula N., Rizvi F., Bajpai A.K., Zhang C., Muller-Newen G., Harris K.W., Rao G.N. An essential role for gp130 in neointima formation following arterial injury. Circ. Res. 2007, 100:807-816.
188. Wang T.J. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011, 123:551-565.
189. Wang Y., Lewis D.F., Gu Y., Zhao S., Groome L.J. Elevated maternal soluble Gp130 and IL-6 levels and reduced Gp130 and SOCS-3 expressions in women complicated with preeclampsia. Hypertension 2011, 57:336-342.
190. Wei M., Ren S., Liu J., Li P., Qian H., Tarkka M. Perioperative plasma brain natriuretic peptide and cardiotrophin-1 in off-pump coronary artery bypass. Scand. Cardiovasc. J. 2008, 42:399-404.
191. White U.A., Stephens J.M. The gp130 receptor cytokine family: regulators of adipocyte development and function. Curr. Pharm. Des. 2011, 17:340-346.
192. White U.A., Stewart W.C., Mynatt R.L., Stephens J.M. Neuropoietin attenuates adipogenesis and induces insulin resistance in adipocytes. J. Biol. Chem. 2008, 283:22505-22512.
193. Wiesbauer F., Kaun C., Zorn G., Maurer G., Huber K., Wojta J. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br. J. Pharmacol. 2002, 135:284-292.
194. Wilson W.R., Wills J., Furness P.N., Loftus I.M., Thompson M.M. Abdominal aortic aneurysm rupture is not associated with an up-regulation of inflammation within the aneurysm wall. Eur. J. Vasc. Endovasc. Surg. 2010, 40:191-195.
195. Xu J., Drew P.D. Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J. Immunol. 2007, 178:1904-1913.
196. Yakeu G., Butcher L., Isa S., Webb R., Roberts A.W., Thomas A.W., Backx K., James P.E., Morris K. Low-intensity exercise enhances expression of markers of alternative activation in circulating leukocytes: roles of PPARgamma and Th2 cytokines. Atherosclerosis 2010, 212:668-673.
197. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
198. Yuen C.Y., Wong W.T., Tian X.Y., Wong S.L., Lau C.W., Yu J., Tomlinson B., Yao X., Huang Y. Telmisartan inhibits vasoconstriction via PPARgamma-dependent expression and activation of endothelial nitric oxide synthase. Cardiovasc. Res. 2011, 90:122-129.
199. Zanger D., Yang B.K., Ardans J., Waclawiw M.A., Csako G., Wahl L.M., Cannon R.O. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J. Am. Coll. Cardiol. 2000, 36:1797-1802.
200. 4+ lymphocytes. J. Immunol. 2008, 180:6988-6996.
201. Zhao M., Chang C., Liu Z., Chen L.M., Chen Q. Treatment with low-dose aspirin increased the level LIF and integrin beta3 expression in mice during the implantation window. Placenta 2010, 31:1101-1105.
202. Zhou Q., Liao J.K. Pleiotropic effects of statins - basic research and clinical perspectives. Circ. J. 2010, 74:818-826.
203. Zuliani G., Galvani M., Maggio M., Volpato S., Bandinelli S., Corsi A.M., Lauretani F., Cherubini A., Guralnik J.M., Fellin R., Ferrucci L. Plasma soluble gp130 levels are increased in older subjects with metabolic syndrome. The role of insulin resistance. Atherosclerosis 2010, 213:319-324.